Director, Portfolio Strategy

Location: Menlo Park, CA, Princeton, NJ or Miami, FL onsite

About Summit:

Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational

bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD-1 and VEGF.

Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC), with three active Phase III trials:

• HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a 3rd generation EGFR TKI (e.g., osimertinib).

• HARMONi-3 is a Phase III clinical trial which is designed to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.

• HARMONi-7 is a Phase III clinical trial which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was approved for marketing authorization in China in May 2024. Ivonescimab was granted Fast Track designation by the US Food & Drug Administration (FDA) for the HARMONi clinical trial setting.

Overview of Role:

The Director, Portfolio Strategy position reports to the Executive Director, Portfolio Strategy to support strategic planning activities by providing actionable recommendations based on assessments of markets and competitors, both existing and potential.

Role and Responsibilities:

• Deliver strategic market and competitive intelligence insights through research, scenario planning, and impact assessments to guide executive decision-making and portfolio strategy.
• Conduct deep analysis of competitors, products, and market trends, maintaining real-time awareness of landscape changes and translating insights into strategic implications.
• Develop, lead and execute comprehensive market research plans (qualitative, quantitative, and competitive), selecting vendors, designing studies, interpreting results, and ensuring timely, high-quality deliverables.
• Inform forecasting and revenue modeling for new indications up to 18 months before launch, providing data-driven assumptions for early commercial planning.
• Integrate market research and intelligence into strategic planning, including brand plans, market access, and situation analysis.
• Maintain an in-depth understanding of oncology markets and data sources, synthesizing findings into a central Knowledge Repository for organizational use.
• Partner cross-functionally with Commercial, R&D, Corporate Strategy, Regulatory, and Operations to align insights with portfolio priorities and address emerging business challenges.
• Provide ad hoc analytical support to executive stakeholders to inform R&D, commercial, and business development decisions.
• Leverage best-in-class analytical methodologies and tools to interpret epidemiology, market, and customer data into actionable recommendations.
• Build and manage external partnerships—from market research vendors to data providers—ensuring quality, accountability, and cost-effectiveness.

Experience, Education and Specialized Knowledge and Skills:

• Bachelors Degree in Biotech or related field. Advanced degree preferred
• Minimum of 10+ years of pharmaceuticals/biotech industry experience working with both qualit